Organised developments across research, therapeutics, guidelines, regulation and access — each with a source, date and "why it matters". Not a news feed.
Demand-driven shortages and variable coverage affect who can start newer agents.
Approval does not guarantee that patients can actually obtain therapy.
Thailand's Universal Coverage Scheme continues to expand access to diabetes care and medicines.
Shows how universal financing shapes real-world access in Southeast Asia.
Annual standards continue to prioritise cardiorenal protection and weight management.
Shifts routine care from glucose-only targets toward complication prevention.
Dual GIP/GLP-1 therapy broadens options for glycaemic control and weight.
Changes conversations about sequencing and weight-centric care.
Continuous glucose monitoring metrics increasingly complement HbA1c.
Refines how control is assessed day-to-day.
MOH Malaysia's CPG reinforces metformin-first, target-based care with complication screening.
Standardises diabetes care across public and private sectors.
Educational information only — not medical advice. Verify with the linked sources.